Revision Applications for Validation of Biomarker Assays Developed Through NIH-Supported Research Grants (R01 Clinical Trial Not Allowed)
ID: 350540Type: Posted
Overview

Buyer

National Institutes of Health (HHS-NIH11)

Award Range

$0 - $150K

Eligible Applicants

Others

Funding Category

Health

Funding Instrument

Grant

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes

Original Source

https://grants.gov/search-results-detail/350540

Additional Information

http://grants.nih.gov/grants/guide/pa-files/PAR-24-047.html
Timeline
  1. 1
    Forecast Posted Not available
  2. 2
    Forecast Due Not available
  3. 3
    Posted Oct 10, 2023 12:00 AM
  4. 4
    Due Oct 13, 2026 12:00 AM
Description

The National Institutes of Health (NIH) has posted a grant opportunity titled "Revision Applications for Validation of Biomarker Assays Developed Through NIH-Supported Research Grants (R01 Clinical Trial Not Allowed)". This grant opportunity falls under the category of Health and is a discretionary grant. The grant does not require cost sharing or matching. The purpose of this grant is to accelerate the translation of NCI-supported methods/assays/technologies to the clinic, specifically focusing on the adaptation and clinical validation of molecular/cellular/imaging markers (referred to as "markers" or "biomarkers") for cancer detection, diagnosis, prognosis, monitoring, and prediction of response in treatment, as well as markers for cancer control and prevention. The grant encourages multi-disciplinary interaction among scientific investigators, assay developers, clinicians, statisticians, and clinical laboratory staff. The grant does not support early-stage development of technology or the conduct of clinical trials, but rather the adaptation and validation of assays to the point where they could be integrated into clinical trials as investigational assays/tools/devices. The grant has a closing date of October 13, 2026, and an award ceiling of $150,000. For more information and to apply, visit the following link: Additional Information. For any inquiries, contact NIH Grants Information at grantsinfo@nih.gov.

Point(s) of Contact
grantsinfo@nih.gov
Files
Title
Posted
PAR-24-047-Full-Announcement.html
4/10/2024
Similar Opportunities
Assay Validation of High Quality Markers for Clinical Studies in Cancer (UH3 Clinical Trials Not Allowed)
Active
National Institutes of Health
The National Institutes of Health (NIH) is offering a federal grant opportunity titled "Assay Validation of High Quality Markers for Clinical Studies in Cancer (UH3 Clinical Trials Not Allowed)". This grant aims to accelerate the adoption and validation of molecular/cellular/imaging markers and assays for various purposes in cancer research, including detection, diagnosis, prognosis, monitoring, prediction of response or resistance to treatment, as well as markers for cancer prevention and control. The grant also supports the validation of pharmacodynamic markers and markers of toxicity. Applicants must have analytically validated assays for the intended clinical use of the markers and assays. The UH3 mechanism will provide support for the clinical validation of established assays for up to 3 years using specimens from retrospective or prospective clinical trials or studies. The grant can also be used to validate existing assays for use in other trials, observational studies, or population studies. Efforts to harmonize clinical laboratory tests and investigate the performance and reproducibility of assays across multiple clinical laboratories are also encouraged. This funding opportunity requires multi-disciplinary collaboration among scientific investigators, oncologists, statisticians, and clinical laboratory scientists. It is important to note that this grant is not intended for early-stage development of technology or the conduct of clinical trials, but rather for the validation of assays to the point where they could be integrated into clinical trials or studies as investigational assays. For more information and to apply for this grant, please visit the following link: [Assay Validation of High Quality Markers for Clinical Studies in Cancer (UH3 Clinical Trials Not Allowed)](http://grants.nih.gov/grants/guide/pa-files/PAR-23-314.html).
Revision Applications for Incorporation of Novel NCI-Supported Technology to Accelerate Cancer Research (R01 Clinical Trial Optional)
Active
National Institutes of Health
The National Institutes of Health (NIH) has posted a grant opportunity titled "Revision Applications for Incorporation of Novel NCI-Supported Technology to Accelerate Cancer Research (R01 Clinical Trial Optional)". This grant is in the category of Health and falls under the funding instrument type of Grant. The grant does not require any cost sharing or matching requirement. The opportunity is discretionary and falls under CFDA number 93.394. The purpose of this grant is to encourage revision applications from currently funded NCI R01 research projects. The applicants should propose to expand upon the original research question(s) or otherwise accelerate progress for the parent study by incorporating a new technical approach or instrument developed through support from the NCI Innovative Molecular Analysis Technologies (IMAT) program. The aim is to incentivize independent validation and accelerate the adoption of these emerging technologies by appropriate research communities. This grant aims to promote interdisciplinary collaboration in the development of innovative tools and methods that enable cancer research and accelerate scientific discovery. The grant is open to various eligible applicants, including Alaska Native and Native Hawaiian Serving Institutions, Asian American Native American Pacific Islander Serving Institutions (AANAPISISs), Eligible Agencies of the Federal Government, Faith-based or Community-based Organizations, Hispanic-serving Institutions, Historically Black Colleges and Universities (HBCUs), Indian/Native American Tribal Governments (Other than Federally Recognized), Non-domestic (non-U.S.) Entities (Foreign Organizations), Regional Organizations, Tribally Controlled Colleges and Universities (TCCUs), and U.S. Territory or Possession. The grant has a closing date of October 1, 2024, and the award ceiling is $150,000. For more information and to apply, interested parties can visit the following website: [http://grants.nih.gov/grants/guide/rfa-files/RFA-CA-24-012.html](http://grants.nih.gov/grants/guide/rfa-files/RFA-CA-24-012.html). For any inquiries, the grantor can be contacted at grantsinfo@nih.gov.
Assay Validation of High Quality Markers for Clinical Studies in Cancer (UH2/UH3 Clinical Trial Not Allowed)
Active
National Institutes of Health
The National Institutes of Health is offering a federal grant opportunity titled "Assay Validation of High Quality Markers for Clinical Studies in Cancer (UH2/UH3 Clinical Trial Not Allowed)". This grant aims to support the validation of molecular/cellular/imaging markers and assays for cancer detection, diagnosis, prognosis, monitoring, and prediction of response or resistance to treatment. It also includes markers for cancer prevention and control. The grant will fund both analytical and clinical validation of assays to be used in cancer treatment, control, or prevention trials. The validation of pharmacodynamic markers and markers of toxicity is also supported. The grant requires multi-disciplinary collaboration among scientific investigators, oncologists, statisticians, and clinical laboratory scientists. For more information and to apply, visit the following link: [Assay Validation of High Quality Markers for Clinical Studies in Cancer (UH2/UH3 Clinical Trial Not Allowed)](http://grants.nih.gov/grants/guide/pa-files/PAR-23-313.html).
Integrating Biospecimen Science Approaches into Clinical Assay Development (U01 Clinical Trial Not Allowed)
Active
National Institutes of Health
The National Institutes of Health (NIH) is offering a federal grant opportunity titled "Integrating Biospecimen Science Approaches into Clinical Assay Development (U01 Clinical Trial Not Allowed)". This grant aims to support extramural research in investigating and mitigating challenges faced in clinical assay development and subsequent analytical validation due to preanalytical variability in tumor tissue biopsies, blood biospecimens utilized as liquid biopsies, or other biospecimens. The research funded under this grant will explore the preanalytical variability associated with the procurement and study of various biospecimens, such as small biopsies, blood, tissue swabs, tissue secretions, and bodily fluids. The goal is to improve the understanding of how different preanalytical conditions affect biomarkers and to expedite biomarker clinical assay development through evidence-based standardization of biopsy handling practices. The grant does not require cost sharing or matching and falls under the category of health. The deadline for application submission is September 13, 2024. For more information and to apply, visit the following link: [Integrating Biospecimen Science Approaches into Clinical Assay Development Grant](http://grants.nih.gov/grants/guide/pa-files/PAR-22-049.html).
Revision Applications for Incorporation of Novel NCI- Supported Technology to Accelerate Cancer Research (U01 Clinical Trial Optional)
Active
National Institutes of Health
The National Institutes of Health (NIH) has posted a grant opportunity titled "Revision Applications for Incorporation of Novel NCI-Supported Technology to Accelerate Cancer Research (U01 Clinical Trial Optional)". This opportunity falls under the category of Health and is a Cooperative Agreement. The grant does not require cost sharing or matching. The purpose of this grant is to encourage revision applications from currently funded NCI U01 research projects. The applicants should propose to expand upon the original research question(s) or otherwise accelerate progress for the parent study by incorporating a new technical approach or instrument developed through support from the NCI Innovative Molecular Analysis Technologies (IMAT) program. The aim is to incentivize independent validation and accelerate the suitability of emerging technologies for cancer research. The grant is open to various eligible applicants, including Alaska Native and Native Hawaiian Serving Institutions, Asian American Native American Pacific Islander Serving Institutions (AANAPISISs), Eligible Agencies of the Federal Government, Faith-based or Community-based Organizations, Hispanic-serving Institutions, Historically Black Colleges and Universities (HBCUs), Indian/Native American Tribal Governments (Other than Federally Recognized), Non-domestic (non-U.S.) Entities (Foreign Organizations), Regional Organizations, Tribally Controlled Colleges and Universities (TCCUs), and U.S. Territory or Possession. The close date for this grant is October 1, 2024, and the award ceiling is $150,000. For more information and to apply, please visit the following link: [Grant Information](http://grants.nih.gov/grants/guide/rfa-files/RFA-CA-24-013.html). If you have any inquiries, you can contact NIH Grants Information at grantsinfo@nih.gov.